Presented at the 35th Meeting of the European Society for Radiotherapy and Oncology (ESTRO 35) 29 April-03 May, 2016, Turin, Italy.
To report grade ≥2 overall late rectal and urinary toxicities in patients (pts) with prostate cancer treated by intensity-modulated radiotherapy (IMRT) at 3 dose-levels. Identify predictors of radiation toxicity and report biochemical progression free survival (bPFS).
A total of 277 pts were treated with 70Gy (10.8%), 74Gy (63.9%) and 80 Gy (25.3%) using IMRT without pelvic irradiation were analyzed. Short or long-course androgen deprivation therapy (ADT) was allowed in 46.1% of pts. The toxicity was described using the Common Terminology Criteria for Adverse Events (CTCAE) v4.0 scale. Cox regression models addressed demographics, disease and dosimetry characteristics as potential predictors of late grade ≥2 toxicity after adjusting for other modifying factors.
The median follow-up was 77 months (range 15; 150). There was no grade ≥4 toxicity. The 5-year cumulative rate of grade ≥2 late rectal and urinary toxicities was 6.3% (95% CI = 3.8%; 10.3%) and 25.3% (95% CI = 19.8%; 31.8%) respectively. In multivariate analysis, only the dose (80Gy vs 74 and 70Gy) was found to increase the risk of rectal toxicity (HR = 2.96 [1.07; 8.20]). For pts receiving 74 Gy, International Prostate Symptom Score (IPSS) at baseline ≥8 (HR = 2.40 [1.08; 5.35]) and dose ≥73Gy delivered in more than 2% of bladder (D2%) were found to be predictors of bladder toxicity (HR = 3.29 [1.36; 7.98]). The 5–year biochemical relapse free survival was 81.0% [74.5%; 86.0%] in the entire population, 97.5% [83.5%; 99.6%] in the low risk group, 84.9% [76.7%; 90.3%] in the intermediate risk group and 66.4% [51.8%; 77.4%] in the high-risk group. D’Amico low (HR = 0.09 [0.01; 0.69]) and intermediate risk groups (HR = 0.50 [0.28; 0.88]) as well as PSA nadir ≥0.2 ng/ml (HR = 1.79 [1.01; 3.21]) were predictive of biochemical relapse.
The rate of late rectal toxicity increased with higher doses, while Dmax ≥74Gy, D2% ≥ 73Gy for bladder wall and baseline IPSS ≥8 increased late urinary toxicity.
Syndikus I, Morgan RC, Sydes MR, Graham JD, Dearnaley DP. Late gastrointestinal toxicity after dose-escalated conformal radiotherapy for early prostate cancer: results from the UK Medical Research Council RT01 trial (ISRCTN47772397). Int J Radiat Oncol Biol Phys. 2010;77:773–83. CrossRefPubMedPubMedCentral
Roach 3rd M, Hanks G, Thames Jr H, Schellhammer P, Shipley WU, Sokol GH, Sandler H. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 2006;65:965–74. CrossRefPubMed
American Society for Therapeutic Radiology and Oncology. consensus statement:guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys. 1997;37:1035–41.
Barry MJ, O’Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK, Cockett ATFFJJ. The American urological association symptom index for benign prostatic hyperplasia. The measurement commettee of the American Urological Association. J Urol. 1992;148:1549–57. PubMed
Sauerbrei W. The use of resampling methods to simplify regression models in medical statistics. J R Stat Soc Ser C Appl Stat. 1999;48:313–29. CrossRef
Sundar S, Walker G, Pascoe A. Should elderly prostate cancer patients with comorbidity be spared from prostate radiation dose escalation? Clin Oncol (R Coll Radiol). 2016;28:227–8. CrossRef
Wortel RC, Incrocci L, Pos FJ, van der Heide UA, Lebesque JV, Aluwini S, et al. Late side effects after image guided intensity modulated radiation therapy compared to 3D-conformal radiation therapy for prostate cancer: results from 2 prospective cohorts. Int J Radiat Oncol Biol Phys. 2016;95:680–9. CrossRefPubMed
Pederson AW, Fricano J, Correa D, Pelizzari CA, Liauw SL. Late toxicity after intensity-modulated radiation therapy for localized prostate cancer: An exploration of dose-volume histogram parameters to limit genitourinary and gastrointestinal toxicity. Int J Radiat Oncol Biol Phys. 2012;82:235–41. CrossRefPubMed
Beckendorf V, Guerif S, Le Prise E, Cossett JM, Le Floch O, Chauvet B, et al. 2210 Late Toxicity in the GETUG 06 Randomized Trial Comparing 70 Gy and 80 Gy for Localized Prostate Cancer. Int J Radiat Oncol Biol Phys. 2007;69(3 Suppl):S319. CrossRef
Goldner G, Wachter-Gerstner N, Wachter S, Dieckmann K, Janda M, Pötter R. Acute side effects during 3-D-planned conformal radiotherapy of prostate cancer. Differences between patient’s self-reported questionnaire and the corresponding doctor’s report. Strahlenther Onkol. 2003;179:320–7. CrossRefPubMed
- Intensity-modulated radiation therapy from 70Gy to 80Gy in prostate cancer: six- year outcomes and predictors of late toxicity
- BioMed Central
Neu im Fachgebiet Onkologie
Mail Icon II